Vorarlberger Krankenhaus-Betriebsgesellschaft mbH — Clinical Trial Site

42 Registered trials

22 Currently recruiting

Organisation

Vorarlberger Krankenhaus-Betriebsgesellschaft mbH

Location

Feldkirch, Austria

Identifier

ORG-100021098

Address

Carl-Pedenz-Strasse 2, 6900, Austria

Departments

4101:Interne Medizin
Abteilung fuer Kinder und Jugenheilkunde
Abteilung für Dermatologie und Venerologie
Department of Internal Medicine 3 – Nephrology, Dialysis and Hypertensiology
Department of Internal Medicine II
Department of Internal Medicine III
Department of Internal Medicine III – Nephrology, Dialysis and Hypertensiology
Department of Oncology
Division of Paediatric and Adolescent Medicine
Genecology and Obstetrics
General, Visceral and Thoracic Surgery
Internal E at LKH Rankweil
Internal E department at LKH Rankweil, Valdunastrasse 16, 6830 Rankweil, Austria
Internal Medicine
Internal Medicine II
Internal Medicine II at LKH Rankweil
Internal Medicine II Oncology, Hematology, Gastroenterology, Infectiology
Internal Medicine II, Interne E
Internal Medicine II, Interne E (Hematology and Oncology)
Internal Medicine II, Oncology - Internal E
Internal Medicine III Nephrology, Dialysis and Hypertension
Interne Abteilung, Station Interne E, Onkologie
Interne E
Interne E (Hämatologie und Onkologie)
Interne E am LKH Rankweil
Interne E at LHK Rankwell
Koop. Gruppe Gyn./Int. Abteilung
Landeskrankenhaus Feldkirch
Landeskrankenhaus Feldkirch, Department of Internal Medicine E at Landeskrankenhaus Rankweil
LKH Rankweil, Department of Internal Medicine II, Interne E
Onkologie, Hämatologie
VIVIT Institute
Vorarlberg Institute for Vascular Investigation and Treatment
Vorarlberg Institute for Vascular Research (VIVIT), Specialist Hospital, Internal Medicine I

Clinical trials at this site (42)

Search interface

OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50% Pending

2025-523586-18-00 Non-Small Cell Lung Cancer 5
A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific… Recruiting

2025-522767-15-00 Acute Myeloid Leukemia 5 2026-01-27
STOP-PKD: SGLT2-inhibition to improve Prognosis in Polycystic Kidney Disease Recruiting

2025-521276-59-00 Autosomal dominant polycystic kidney disease (ADPKD) 5 2025-12-16
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia … Recruiting

2024-512753-24-00 Acute Myeloid Leukemia (AML) 5 2025-08-05
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Pso… Recruiting

2024-515706-77-00 Moderate to Severe Plaque Psoriasis 5 2025-05-08
A study investigating the effect of adding revumenib to treatment with venetoclax + azacitidine in patients with acute myeloid leukemia (AML… Recruiting

2024-512733-32-00 Acute Myeloid Leukemia (AML) 5 2025-03-31
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN). Recruiting

2024-514135-17-00 Immunoglobulin A Nephropathy 5 2024-11-28
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and how Drug Move… Recruiting

2022-501599-25-00 juvenile idiopathic arthritis 5 2024-03-19
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan… Recruiting

2023-505749-14-00 c-Met overexpressing EGFR wildtype non-squamous non-sma 5 2022-03-20
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib in RET fusion-Positive NSCLC Recruiting

2023-506784-33-00 RET fusion-Positive NSCLC 5 2021-01-19
A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC Recruiting

2023-509628-16-00 Small Cell Lung Cancer (SCLC) 5 2026-05-07
A trial to learn how effective and safe datopotamab deruxtecan (Dato-DXd) is compared to docetaxel and how well Dato-DXd works in adults wit… Recruiting

2024-520101-39-00 TROP2 NMR-positive advanced or metastatic non-squamous 5 2026-04-01
A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg… Recruiting

2025-523083-21-00 PIK3CA-mutant Hormone Receptor Positive, Human Epiderma 5 2025-12-08
A Study of BMS-986504 in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line M… Recruiting

2025-521511-40-00 metastatic non-small cell lung cancer 10 2025-11-18
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
A global phase III study to investigate the effectiveness and safety of rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot… Recruiting

2024-514281-39-00 Metastatic Squamous Non-small Cell Lung Cancer Whose Tu 5 2025-02-14
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca… Recruiting

2022-502352-31-00 Colorectal Cancer (CRC) 5 2025-02-10
A trial to learn if Dato-DXd with rilvegostomig, or rilvegostomig alone, is safe and works compared with pembrolizumab in people who have ad… Recruiting

2023-505077-32-00 Locally-advanced or metastatic non-squamous non-small c 5 2025-01-28
A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe… Recruiting

2023-503412-33-00 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small 5 2024-03-29
An international randomised trial of radical surgery followed by adjuvant therapy versus no further treatment in patients with early-stage, … Recruiting

2023-504973-19-01 early-stage, intermediate-risk cervical cancer 5 2023-09-06
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Dia… Recruiting

2023-510384-36-00 Newly Diagnosed Multiple Myeloma 5 2022-09-13
FI-3, Fidelia Recruiting

2024-518243-38-00 Fecal incontinence in female and male patients 5 2022-04-20
Apremilast Study in Children with Active Juvenile Psoriatic Arthritis Recruiting

2023-503435-17-00 Juvenile psoriatic arthritis 5 2021-03-31